

July 2, 2008

WRITER'S DIRECT NUMBER: (202) 772-8679 INTERNET ADDRESS: TSHEA@SKGF.COM

Art Unit 1633

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application

Application No. 10/633,699; Filed: August 5, 2003

Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity

Inventors: UMAÑA et al.

Our Ref: 1975.0010004/TJS/T-M/M-N

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Fourth Supplemental Information Disclosure Statement:
- Form PTO/SB/08B (1 sheet) listing 2 documents (NPL21-NPL22);
- 3. Copies of cited documents (NPL21-NPL22).

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Attorney for Applicants Registration No. 41,306

TIS/T-M/M-N/Ird Enclosures

841995 1.DOC